SCHEMBL14601427

SCHEMBL14601427

Oc1ccc2nc(-c3ccc(Cl)cc3)n(CCc3cccs3)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HPGD P15428 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
MAPT P10636 1/20 0.40
ESR1 P03372 1/20 0.39
TP53 P04637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
JAK2 O60674 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14601419 0.89 KDM4E (0.43) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL14601423 0.89 GRIA1 (0.45) ALDH1A1KDM4ELMNAHPGDSMN1; SMN2
SCHEMBL14601418 0.89 JAK2 (0.42) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL14601428 0.86 KDM4E (0.54) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL14601416 0.85 KDM4E (0.38) ALDH1A1KDM4ELMNARAB9AHPGD
SCHEMBL14601424 0.85 HPGD (0.40) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL14601422 0.85 PTGS2 (0.43) PIK3CDPIK3CAPIK3CBPIK3CGMAOB
SCHEMBL14601420 0.84 KDM4E (0.57) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL14601425 0.82 KDM4E (0.47) ALDH1A1KDM4ELMNANPC1RAB9A
SCHEMBL14601421 0.80 KDM4E (0.39) ALDH1A1KDM4ELMNARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed
US-20070004713-A1 Therapeutic benimidazole compounds ASTRAZENECA AB (SE) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004713-A1 Therapeutic benimidazole compounds ESR2, ESRRA, ESRRB ALDH1A1 307/4885MEN1 3071/4885KMT2A 4156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.